鎌状赤血球症治療の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント予測、2024年～2030年

鎌状赤血球症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の鎌状赤血球症治療市場規模は2030年までに74億2,000万米ドルに達し、予測期間中に15.7%のCAGRを記録すると予測されています。

研究開発への投資の増加、対象人口の増加、認知度向上プログラムの増加、有利な政府の取り組みなど、いくつかの要因が成長を促進すると予測されています。欧州鎌状赤血球連盟によると、欧州では約7万人が鎌状赤血球症（SCD）を患っています。

SCDの検出を容易にする非侵襲的で技術的に高度なデジタル技術のイントロダクションは、標的鎌状赤血球の診断と治療管理に関連する障壁の克服を支援するように設定されています。現在開発されているPOC装置は、デンシトメトリー、ラテラルフロー免疫測定法、マイクロ流体電気泳動法などの手法に基づいています。鎌状赤血球症の診断率の増加は、成長をさらに促進すると思われます。

鎌状赤血球症に対する利用可能な治療法は通常、症状の緩和と緩和ケアを提供するものです。これらの治療法には一般的に輸血、骨髄移植、薬物療法が含まれます。しかし、骨髄移植はごく一部の患者にしか勧められない唯一の治癒可能性のある治療法です。さらに、Global Blood Therapeutics, Inc.のOxbryta、Emmaus Medical, Inc.のEndari、Agios Pharmaceuticals, Inc.のPYRUKYNDなどの新薬の承認が増加しており、市場成長の原動力になると予想されます。

市場プレーヤーと政府・非政府組織との協力関係の増加は、予測期間中の市場成長を促進すると予想されます。例えば、2021年2月、ノバルティスAGとビル&メリンダ・ゲイツ財団は、鎌状赤血球症の新規遺伝子治療を開発するために協力しました。この合意によると、ビル＆メリンダ・ゲイツ財団は、鎌状赤血球症を治療するための新規治療法の開発を支援するために資金を提供します。

アンメット・メディカル・ニーズの高さ、強力なパイプライン、患者数の増加は、市場成長に影響を与えると予想される主要因です。近年、鎌状赤血球貧血に対する費用対効果の高い薬剤や遺伝子治療に対する需要は、永久的な治療法がないことや骨髄移植に伴うリスクのために高まっています。ブルーバード・バイオ社、ベリカム・ファーマシューティカルズ社、ガミダセル社などの企業は、鎌状赤血球症治療に有効な新たな遺伝子治療薬の開発に積極的に取り組んでおり、今後数年間で治療率が上昇すると予想されます。

voxelotor、crizanlizumab、Altemia、rivipanselのような後期段階のパイプライン医薬品の発売が期待され、予測期間中に鎌状赤血球病産業を牽引すると予測されます。鎌状赤血球症の経済的負担を軽減し、医療施設へのアクセスを向上させ、早期診断、その後の治療、緩和ケアのための様々なサービスを提供するためには、各国によるヘルスケアへの取り組みが不可欠です。

鎌状赤血球症治療市場レポートハイライト

• 治療法に基づくと、輸血分野が2023年の市場を独占しました。SCDを管理するための処置数の多さと、主に採用されている治療オプションが、このセグメントのシェアを支えています。
• 最終用途別では、病院がこの疾患の治療と診断の主要な拠点となっていることから、病院セグメントが2023年に最大の市場シェアを占めました。
• 北米は2023年に37.87％以上のシェアを占めて世界市場を独占したが、アジア太平洋地域は予測期間中に最も速いCAGRで成長すると予測されています。
• 市場開拓の主なプレーヤーは、予測期間中に市場シェアを拡大するために、新製品開発、M&Aなどいくつかの戦略を行っています。

目次

第1章 調査範囲と目的

第2章 エグゼクティブサマリー

第3章 市場変数、動向、範囲

• 市場系統の見通し
• 鎌状赤血球症治療の市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 鎌状赤血球症治療市場：ビジネス環境分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
• 普及と成長の見通しマッピング
• COVID-19感染症が鎌状赤血球症治療市場に与える影響

第4章 鎌状赤血球症治療市場：治療分析

• 鎌状赤血球症治療薬市場シェア分析、2018年および2030年
• 鎌状赤血球症治療市場：セグメントダッシュボード：
• 治療セグメントの市場規模、予測、動向分析、2018年から2030年まで
  • 骨髄移植
  • 輸血
  • 薬物療法

第5章 鎌状赤血球症治療市場：最終用途分析

• 鎌状赤血球症治療の最終用途市場シェア分析、2018年および2030年
• 鎌状赤血球症治療の最終用途市場：セグメントダッシュボード
• 最終用途セグメントの市場規模、予測、動向分析、2018年から2030年
  • 病院
  • 専門クリニック
  • その他

第6章 鎌状赤血球症治療市場：地域分析

• 地域別市場シェア、2023年および2030年
• 北米
  • SWOT分析
  • 北米市場、2018～2030年
  • 米国
  • カナダ
• 欧州
  • SWOT分析
  • 欧州市場、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • SWOT分析
  • アジア太平洋地域市場、2018～2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • SWOT分析
  • ラテンアメリカ市場、2018～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • SWOT分析
  • MEA鎌状赤血球症市場、2018年～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合分析

• 企業の分類
• 戦略マッピング
  • 新製品の発売
  • パートナーシップ
  • 取得
  • コラボレーション
• 企業プロファイル
  • Novartis AG
  • Pfizer Inc.
  • bluebird bio, Inc.
  • GlycoMimetics
  • Emmaus Medical, Inc.
  • Bristol-Myers Squibb Company
  • CRISPR Therapeutics
  • Graphite Bio, Inc.

List of Tables

• Table 1 North America sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
• Table 2 North America sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 3 North America Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 4 U.S. sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 5 U.S. Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 6 Canada sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 7 Canada Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 8 Europe sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
• Table 9 Europe sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 10 Europe Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 11 UK sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 12 UK Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 13 Germany sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 14 Germany Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 15 France sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 16 France Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 17 Italy sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 18 Italy Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 19 Spain sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 20 Spain Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 21 Denmark sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 22 Denmark Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 23 Sweden sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 24 Sweden Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 25 Norway sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 26 Norway Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 27 Asia Pacific sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 30 Japan sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 31 Japan Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 32 China sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 33 China Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 34 India sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 35 India Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 36 Australia sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 37 Australia Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 38 South Korea sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 39 South Korea Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 40 Thailand sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 41 Thailand Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 42 Latin America sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
• Table 43 Latin America sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 44 Latin America Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 45 Brazil sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 46 Brazil Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 47 Mexico sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 48 Mexico Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 49 Argentina sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 50 Argentina Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 51 MEA sickle cell disease treatment market, by country, 2018 - 2030 (USD Million)
• Table 52 MEA sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 53 MEA Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 54 South Africa sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 55 South Africa Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 56 Saudi Arabia sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 57 Saudi Arabia Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 58 UAE sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 59 UAE Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)
• Table 60 Kuwait sickle cell disease treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 61 Kuwait Sickle Cell Disease Treatment Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Value chain-based sizing & forecasting
• Fig. 4 QFD modeling for market share assessment
• Fig. 5 Market summary, 2023
• Fig. 6 Market trends & outlook
• Fig. 7 Market segmentation & scope
• Fig. 8 Market driver relevance analysis (Current & future impact)
• Fig. 9 Market restrain relevance analysis (Current & future impact)
• Fig. 10 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 11 Porter's Five Forces Analysis
• Fig. 12 Sickle cell disease treatment market treatment outlook key takeaways
• Fig. 13 Sickle cell disease treatment market: Treatment movement analysis
• Fig. 14 Global bone marrow transplant market, 2018 - 2030 (USD Million)
• Fig. 15 Global blood transfusion market, 2018 - 2030 (USD Million)
• Fig. 16 Global pharmacotherapy market, 2018 - 2030 (USD Million)
• Fig. 17 Sickle cell disease treatment market End-use outlook key takeaways
• Fig. 18 Sickle cell disease treatment market: End-use movement analysis
• Fig. 19 Global Hospitals market, 2018 - 2030 (USD Million)
• Fig. 20 Global Specialty Clinics market, 2018 - 2030 (USD Million)
• Fig. 21 Global other market, 2018 - 2030 (USD Million)
• Fig. 22 Regional marketplace: Key takeaways
• Fig. 23 Regional marketplace: Key takeaways
• Fig. 24 North America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Key country dynamics
• Fig. 26 U.S. sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Key country dynamics
• Fig. 28 Canada sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Europe sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Key country dynamics
• Fig. 31 UK sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Key country dynamics
• Fig. 33 Germany sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Key country dynamics
• Fig. 35 France sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 Key country dynamics
• Fig. 37 Spain sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Key country dynamics
• Fig. 39 Italy sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Key country dynamics
• Fig. 41 Denmark sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Key country dynamics
• Fig. 43 Sweden sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Key country dynamics
• Fig. 45 Norway sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Rest of Europe sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD, Million)
• Fig. 47 Asia Pacific sickle cell disease treatment market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Key country dynamics
• Fig. 49 Japan sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Key country dynamics
• Fig. 51 China sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Key country dynamics
• Fig. 53 India sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Key country dynamics
• Fig. 55 South Korea sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 South Korea reimbursement scenario
• Fig. 57 Key country dynamics
• Fig. 58 Australia sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Key country dynamics
• Fig. 60 Thailand sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Rest of Asia Pacific sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Latin America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Key country dynamics
• Fig. 64 Brazil sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Key country dynamics
• Fig. 66 Mexico sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Argentina sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Rest of Latin America sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 MEA sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 South Africa sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Saudi Arabia sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 UAE sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Kuwait sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Rest of MEA sickle cell disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Key company categorization
• Fig. 81 Company categorization
• Fig. 82 Company market share analysis, 2023
• Fig. 83 Strategic framework

Sickle Cell Disease Treatment Market Growth & Trends:

The global sickle cell disease treatment market size is expected to reach USD 7.42 billion by 2030, registering a CAGR of 15.7% during the forecast period, according to a new report by Grand View Research, Inc. Several factors including increased investments in R&D, a growing target population, increasing awareness programs, and favorable government initiatives are anticipated to drive the growth. According to the European Sickle Cell Federation, around 70 thousand people are living with sickle cell disease (SCD) in Europe.

The introduction of noninvasive, technologically advanced, and digital technologies to facilitate the detection of SCD is set to assist in overcoming the barriers associated with targeted sickle cell diagnosis and treatment management. Presently developed POC devices are based on methodologies such as densitometry, lateral flow immunoassay, and microfluidic electrophoresis. The increase in the diagnosis rate of disease will further facilitate growth.

Available treatments for sickle cell disease usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplants, and pharmacotherapy. However, a bone marrow transplant is the only potentially curative treatment recommended only to a small percentage of patients. Moreover, increasing approval of novel drugs such as Oxbryta by Global Blood Therapeutics, Inc.;Endari by Emmaus Medical, Inc.; and PYRUKYND by Agios Pharmaceuticals, Inc. is expected to drive the market growth.

Increasing collaborations between market players and government and non-government organizations are anticipated to fuel market growth over the forecast period. For instance, in February 2021, Novartis AG and Bill & Melinda Gates Foundation collaborated to develop novel gene therapy for sickle cell disease. According to the agreement, Bill & Melinda Gates Foundation will provide funding to support the development of novel therapy to cure SKD.

High-unmet medical needs, a strong pipeline, and a growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for sickle cell anemia has increased owing to the unavailability of a permanent cure and the risks associated with bone marrow transplants. Companies such as bluebird bio, Inc.; Bellicum Phamaceuticals, Inc.; and Gamida Cell are actively involved in the development of new effective gene therapies for sickle cell disease treatment, which is expected to increase the treatment rate in the coming years.

Expected launches of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel are projected to drive the sickle cell disease industry during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.

Sickle Cell Disease Treatment Market Report Highlights:

• Based on treatment, the blood transfusion segment dominated the market in 2023. The high number of procedures and mostly adopted therapeutic options to manage SCD support the segment share
• Based on end-use, the hospital segment held the largest market share in 2023 as hospitals served as primary centers for treatment and diagnosis of the disease
• North America dominated the global market with a share of more than 37.87% in 2023, whereas the Asia Pacific region is projected to grow at the fastest CAGR over the forecast period
• Key market players are undertaking several strategies such as new product development, mergers & acquisitions to increase their market share over the forecast period.

Table of Contents

Chapter 1 Report Scope and Objectives

• 1.1 Market Segmentation and Scope
  • 1.1.1 Segment Definitions
    • 1.1.1.1 Treatment segment
    • 1.1.1.2 End-use segment
• 1.2 Regional Scope
• 1.3 Estimates and Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 GVR's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary research
• 1.7 Information or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List of Secondary Sources
• 1.11 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Segment Outlook
  • 2.2.1 Treatment
  • 2.2.2 End-use
  • 2.2.3 Region
• 2.3 Competitive Insights

Chapter 3 Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
• 3.2 Sickle cell disease treatment Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increasing prevalence of disease
    • 3.2.1.2 Awareness programs and services
    • 3.2.1.3 Presence of reimbursement policies
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Adverse effects and risks related to the treatment procedure
• 3.3 Sickle cell disease treatment Market: Business Environment Analysis Tools
  • 3.3.1 PORTER'S Five Forces Analysis
    • 3.3.1.1 Threat of new entrants
    • 3.3.1.2 Bargaining power of suppliers
    • 3.3.1.3 Bargaining power of buyers
    • 3.3.1.4 Competitive rivalry
    • 3.3.1.5 Threat of substitutes
  • 3.3.2 PESTEL Analysis
    • 3.3.2.1 Political & Legal
    • 3.3.2.2 Economic & Social
    • 3.3.2.3 Technological
• 3.4 Penetration & Growth Prospect Mapping
• 3.5 Impact of COVID-19 on the sickle cell disease treatment market

Chapter 4 Sickle Cell Disease Treatment Market: Treatment Analysis

• 4.1 Sickle Cell Disease Treatment Treatment Market Share Analysis, 2018 & 2030
• 4.2 Sickle Cell Disease Treatment Treatment Market: Segment Dashboard:
• 4.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Treatment Segment
  • 4.3.1 Bone Marrow Transplant
    • 4.3.1.1 Bone marrow transplant market, 2018 - 2030 (USD Million)
  • 4.3.2 Blood Transfusion
    • 4.3.2.1 Blood transfusion market, 2018 - 2030 (USD Million)
  • 4.3.3 Pharmacotherapy
    • 4.3.3.1 Pharmacotherapy market, 2018 - 2030 (USD Million)

Chapter 5 Sickle Cell Disease Treatment Market: End-use Analysis

• 5.1 Sickle Cell Disease Treatment End-use Mode Market Share Analysis, 2018 & 2030
• 5.2 Sickle Cell Disease Treatment End-use Mode Market: Segment Dashboard
• 5.3 Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the End-use Mode Segment
  • 5.3.1 Hospitals
    • 5.3.1.1 Hospitals market, 2018 - 2030 (USD Million)
  • 5.3.2 Specialty Clinics
    • 5.3.2.1 Specialty Clinics market, 2018 - 2030 (USD Million)
  • 5.3.3 Others
    • 5.3.3.1 Others market, 2018 - 2030 (USD Million)

Chapter 6 Sickle Cell Disease Treatment Market: Regional Analysis

• 6.1. Sickle Cell Disease Market Share By Region, 2023 & 2030
• 6.2. North America
  • 6.2.1. SWOT Analysis
  • 6.2.2. North America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.2.3. U.S.
    • 6.2.3.1. Key Country Dynamics
    • 6.2.3.2. Target Disease Prevalence
    • 6.2.3.3. Competitive Scenario
    • 6.2.3.4. Regulatory Framework
    • 6.2.3.5. U.S. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.2.4. Canada
    • 6.2.4.1. Key Country Dynamics
    • 6.2.4.2. Target Disease Prevalence
    • 6.2.4.3. Competitive Scenario
    • 6.2.4.4. Regulatory Framework
    • 6.2.4.5. Canada Sickle Cell Disease Market, 2018 - 2030 (USD Million)
• 6.3. Europe
  • 6.3.1. SWOT Analysis
  • 6.3.2. Europe Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.3. UK
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Target Disease Prevalence
    • 6.3.3.3. Competitive Scenario
    • 6.3.3.4. Regulatory Framework
    • 6.3.3.5. UK Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.4. Germany
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Target Disease Prevalence
    • 6.3.4.3. Competitive Scenario
    • 6.3.4.4. Regulatory Framework
    • 6.3.4.5. Germany Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.5. France
    • 6.3.5.1. Key Country Dynamics
    • 6.3.5.2. Target Disease Prevalence
    • 6.3.5.3. Competitive Scenario
    • 6.3.5.4. Regulatory Framework
    • 6.3.5.5. France Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.6. Italy
    • 6.3.6.1. Key Country Dynamics
    • 6.3.6.2. Target Disease Prevalence
    • 6.3.6.3. Competitive Scenario
    • 6.3.6.4. Regulatory Framework
    • 6.3.6.5. Italy Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.7. Spain
    • 6.3.7.1. Key Country Dynamics
    • 6.3.7.2. Target Disease Prevalence
    • 6.3.7.3. Competitive Scenario
    • 6.3.7.4. Regulatory Framework
    • 6.3.7.5. Spain Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.8. Denmark
    • 6.3.8.1. Key Country Dynamics
    • 6.3.8.2. Target Disease Prevalence
    • 6.3.8.3. Competitive Scenario
    • 6.3.8.4. Regulatory Framework
    • 6.3.8.5. Denmark Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.9. Sweden
    • 6.3.9.1. Key Country Dynamics
    • 6.3.9.2. Target Disease Prevalence
    • 6.3.9.3. Competitive Scenario
    • 6.3.9.4. Regulatory Framework
    • 6.3.9.5. Sweden Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.3.10. Norway
    • 6.3.10.1.Key Country Dynamics
    • 6.3.10.2.Target Disease Prevalence
    • 6.3.10.3.Competitive Scenario
    • 6.3.10.4.Regulatory Framework
    • 6.3.10.5.Norway Sickle Cell Disease Market, 2018 - 2030 (USD Million)
• 6.4. Asia Pacific
  • 6.4.1. SWOT Analysis
  • 6.4.2. Asia Pacific Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4.3. Japan
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Competitive Scenario
    • 6.4.3.4. Regulatory Framework
    • 6.4.3.5. Japan Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4.4. China
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Competitive Scenario
    • 6.4.4.4. Regulatory Framework
    • 6.4.4.5. China Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4.5. India
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Target Disease Prevalence
    • 6.4.5.3. Competitive Scenario
    • 6.4.5.4. Regulatory Framework
    • 6.4.5.5. India Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4.6. Australia
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Target Disease Prevalence
    • 6.4.6.3. Competitive Scenario
    • 6.4.6.4. Regulatory Framework
    • 6.4.6.5. Australia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4.7. Thailand
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Target Disease Prevalence
    • 6.4.7.3. Competitive Scenario
    • 6.4.7.4. Regulatory Framework
    • 6.4.7.5. Thailand Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.4.8. South Korea
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Target Disease Prevalence
    • 6.4.8.3. Competitive Scenario
    • 6.4.8.4. Regulatory Framework
    • 6.4.8.5. South Korea Sickle Cell Disease Market, 2018 - 2030 (USD Million)
• 6.5. Latin America
  • 6.5.1. SWOT Analysis
  • 6.5.2. Latin America Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.5.3. Brazil
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Competitive Scenario
    • 6.5.3.4. Regulatory Framework
    • 6.5.3.5. Brazil Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.5.4. Mexico
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Competitive Scenario
    • 6.5.4.4. Regulatory Framework
    • 6.5.4.5. Mexico Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.5.5. Argentina
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Competitive Scenario
    • 6.5.5.4. Regulatory Framework
    • 6.5.5.5. Argentina Sickle Cell Disease Market, 2018 - 2030 (USD Million)
• 6.6. MEA
  • 6.6.1. SWOT Analysis
  • 6.6.2. MEA Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.6.3. South Africa
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Competitive Scenario
    • 6.6.3.4. Regulatory Framework
    • 6.6.3.5. South Africa Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.6.4. Saudi Arabia
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Competitive Scenario
    • 6.6.4.4. Regulatory Framework
    • 6.6.4.5. Saudi Arabia Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.6.5. UAE
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Competitive Scenario
    • 6.6.5.4. Regulatory Framework
    • 6.6.5.5. UAE Sickle Cell Disease Market, 2018 - 2030 (USD Million)
  • 6.6.6. Kuwait
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Competitive Scenario
    • 6.6.6.4. Regulatory Framework
    • 6.6.6.5. Kuwait Sickle Cell Disease Market, 2018 - 2030 (USD Million)

Chapter 7 Competitive Analysis

• 7.1 Company Categorization
• 7.2 Strategy Mapping
  • 7.2.1 New product launch
  • 7.2.2 Partnerships
  • 7.2.3 Acquisition
  • 7.2.4 Collaboration
• 7.3 Company Profiles
  • 7.3.1 Novartis AG
    • 7.3.1.1 Company overview
    • 7.3.1.2 Financial performance
    • 7.3.1.3 Product benchmarking
    • 7.3.1.4 Strategic initiatives
  • 7.3.2 Pfizer Inc.
    • 7.3.2.1 Company overview
    • 7.3.2.2 Financial performance
    • 7.3.2.3 Product benchmarking
    • 7.3.2.4 Strategic initiatives
  • 7.3.3 bluebird bio, Inc.
    • 7.3.3.1 Company overview
    • 7.3.3.2 Financial performance
    • 7.3.3.3 Product benchmarking
    • 7.3.3.4 Strategic initiatives
  • 7.3.4 GlycoMimetics
    • 7.3.4.1 Company overview
    • 7.3.4.2 Financial performance
    • 7.3.4.3 Product benchmarking
    • 7.3.4.4 Strategic initiatives
  • 7.3.5 Emmaus Medical, Inc.
    • 7.3.5.1 Company overview
    • 7.3.5.2 Financial performance
    • 7.3.5.3 Product benchmarking
    • 7.3.5.4 Strategic initiatives
  • 7.3.6 Bristol-Myers Squibb Company
    • 7.3.6.1 Company overview
    • 7.3.6.2 Financial performance
    • 7.3.6.3 Product benchmarking
    • 7.3.6.4 Strategic initiatives
  • 7.3.7 CRISPR Therapeutics
    • 7.3.7.1 Company overview
    • 7.3.7.2 Financial performance
    • 7.3.7.3 Product benchmarking
    • 7.3.7.4 Strategic initiatives
  • 7.3.8 Graphite Bio, Inc.
    • 7.3.8.1 Company overview
    • 7.3.8.2 Financial performance
    • 7.3.8.3 Product benchmarking
    • 7.3.8.4 Strategic initiatives